4.7 Review

How to design a study to evaluate therapeutic drug monitoring in infectious diseases?

Journal

CLINICAL MICROBIOLOGY AND INFECTION
Volume 26, Issue 8, Pages 1008-1016

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.cmi.2020.03.008

Keywords

Drug exposure; Personalized dosing study design; Pharmacodynamics; Pharmacokinetics; Randomized controlled trials; Therapeutic drug monitoring

Funding

  1. Marie Sklodowska-Curie Actions [713660]
  2. NHMRC [APP1099352, APP1117065]

Ask authors/readers for more resources

Background: Therapeutic drug monitoring (TDM) is a tool to personalize and optimize dosing by measuring the drug concentration and subsequently adjusting the dose to reach a target concentration or exposure. The evidence to support TDM is however often ranked as expert opinion. Limitations in study design and sample size have hampered definitive conclusions of the potential added value of TDM. Objectives: We aim to give expert opinion and discuss the main points and limitations of available data from antibiotic TDM trials and emphasize key elements for consideration in design of future clinical studies to quantify the benefits of TDM. Sources: The sources were peer-reviewed publications, guidelines and expert opinions from the field of TDM. Content: This review focuses on key aspects of antimicrobial TDM study design: describing the rationale for a TDM study, assessing the exposure of a drug, assessing susceptibility of pathogens and selecting appropriate clinical endpoints. Moreover we provide guidance on appropriate study design. (C) 2020 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available